Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 4/20 | 0.48 |
| ▸ | AURKA | O14965 | 4/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.46 |
| ▸ | EPHB4 | P54760 | 5/20 | 0.45 |
| ▸ | BTK | Q06187 | 2/20 | 0.43 |
| ▸ | LYN | P07948 | 1/20 | 0.42 |
| ▸ | TXK | P42681 | 1/20 | 0.42 |
| ▸ | SYK | P43405 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.41 |
| ▸ | CSK | P41240 | 1/20 | 0.41 |
| ▸ | JAK3 | P52333 | 1/20 | 0.41 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2465824 | 0.85 | EPHB4 (0.49) | GRM4AURKAAURKBEPHB4BTK | |
| SCHEMBL14650714 | 0.82 | BTK (0.48) | AURKAAURKBEPHB4BTKLYN | |
| SCHEMBL14633934 | 0.81 | BTK (0.49) | GRM4EPHB4BTKLYNTXK | |
| SCHEMBL14633535 | 0.80 | GRM4 (0.46) | GRM4AURKAAURKBEPHB4BTK | |
| SCHEMBL14634174 | 0.79 | RIPK2 (0.49) | GRM4EPHB4BTKLYNTXK | |
| SCHEMBL2512099 | 0.79 | BTK (0.50) | AURKAAURKBEPHB4BTKLYN | |
| SCHEMBL14650318 | 0.78 | AURKA (0.47) | GRM4AURKAAURKBEPHB4BTK | |
| SCHEMBL12325150 | 0.78 | ABCB11 (0.51) | AURKAAURKBEPHB4BTKLYN | |
| SCHEMBL2467099 | 0.77 | GRM4 (0.40) | GRM4JAK3KDR | |
| SCHEMBL14634250 | 0.77 | TRPA1 (0.48) | GRM4AURKAEPHB4BTKLYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130023532-A1 | INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023532-A1 | INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | MAP3K19, MAP3K1, MAP3K20 | GRM4 4019/4885AURKA 70/4885AURKB 123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.